<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04194593</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL18_0795</org_study_id>
    <nct_id>NCT04194593</nct_id>
  </id_info>
  <brief_title>Biomarker-based Algorithm for Diagnosis of Glioma</brief_title>
  <acronym>TELOGNOSTIC</acronym>
  <official_title>Development of a New Algorithm-based Classification for Glioma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      ATRX (X-linked mental retardation and alpha-thalassaemia syndrome protein) loss and pTERT
      (Telomerase reverse transcriptase) mutation are diagnostic markers of gliomas. However, 4 to
      28% of gliomas shows none of these alterations. The aim of this project is to propose a new
      test able to detect the telomeric status for every glioma. Based on this test and other
      markers (such as mutation of IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate
      dehydrogenase 2)), investigators propose an algorithm, able to classify the main subtypes of
      gliomas (astrocytoma, oligodendroglioma and glioblastoma).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determination of the prognosis and diagnosis values of a new qPCR (quantitative polymerase chain reaction) -based biological testing in glioma</measure>
    <time_frame>1 year</time_frame>
    <description>An algorithm will be built, based on the result of this specific biological testing combined with other markers (determined in routine clinical testing). The algorithm parameters will be set using samples with a clear diagnosis (concordant molecular and immuno-histological markers). Then gliomas with uncertain diagnosis will be classified and the global overall survival will be predicted.
Biological testing will be performed during one year and the analyses in terms of disease outcome will be refreshed every year.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">300</enrollment>
  <condition>Glioma</condition>
  <arm_group>
    <arm_group_label>Glioma</arm_group_label>
    <description>FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples will be used for DNA extraction. Different gliomas tumors will be used (oligodendroglioma, astrocytomas, glioblastoma)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PCR (Polymerase Chain Reaction)</intervention_name>
    <description>Biological testing of FFPE (Formalin-Fixed Paraffin-Embedded) or frozen samples of tumors will be led. These tissues have been collected during the treatment of patients (for diagnostic purposes).
A molecular analysis (polymerase chain reaction) is led on DNA extracted from FFPE/frozen conserved tissues, and a result is produced by the algorithm.</description>
    <arm_group_label>Glioma</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        300 samples of gliomas (FFPE and/or frozen tissues)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with a diagnosis of glioma (retrospective),

          -  Patient with available biological material : extracted DNA and/or FFPE tissue and/or
             frozen sample.

          -  Samples are not required any more for diagnosis purpose

          -  Patient with informed consent

        Exclusion Criteria:

          -  Patient with no informed consent

          -  Patients with no available biological sample
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut de Pathologie Est, Biopathologie moléculaire, Hôpitaux Est, HCL</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 11, 2019</study_first_posted>
  <last_update_submitted>December 9, 2019</last_update_submitted>
  <last_update_submitted_qc>December 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

